Case-Based Roundtable Meeting Spotlight November 1 2021

One year after a 75-year-old patient with diffuse large B-cell lymphoma achieved remission following 6 cycles of R-CHOP, the patient relapsed but declined transplant.

After 8 months on enzalutamide, a 75-year-old patients with metastatic castration-resistant prostate cancer showed a PSA level of 60.7 ng/mL, enlargement of known pelvic lymph nodes, and progressive disease.

A 59-year-old Asian man presented with chest pain, cough, and dyspnea. A discussion of the case was led by Shirish M. Gadgeel, MD, during a Targeted Oncology Case-Based Roundtable event.

Rachel B. Salit, MD, discussed the case of a 48-year-old patient with graft-versus-host-disease.

A 51-year-old man presented with worsening fatigue on exertion and pallor, with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was later diagnosed with advanced stage non–small cell lung cancer.

A 75-year-old patient with metastatic castration resistant prostate cancer experienced an increase hip pain and urinary frequency 12 months after external beam radiation therapy plus androgen deprivation therapy.

Twelve months following a thyroidectomy with bilateral central neck dissection and later declining systemic therapy, a 58-year-old man with medullary thyroid cancer was no longer asymptomatic.

How an oncologist treats a patients with non–small cell lung cancer wit the available treatment options is largely dependent on the patient's PD-L1 status.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

A 51-year-old man presented with pallor and worsening fatigue on exertion and was diagnosed with multiple myeloma, standard risk, stage II.

During a Targeted Oncology Case-Based Roundtable event, Melissa L. Johnson, MD, director, discussed the case of 66-year-old man with non–small cell lung cancer.